Breast cancer prognosis and P-cadherin expression: systematic review and study-level meta-analysis. Issue Volume 12:Issue e6(2022) (17th September 2020)
- Record Type:
- Journal Article
- Title:
- Breast cancer prognosis and P-cadherin expression: systematic review and study-level meta-analysis. Issue Volume 12:Issue e6(2022) (17th September 2020)
- Main Title:
- Breast cancer prognosis and P-cadherin expression: systematic review and study-level meta-analysis
- Authors:
- Qi, Runzhi
Lin, Jinyin
Chen, Shuntai
Jiang, Juling
Zhang, Xing
Yao, Bo
Zheng, Honggang
Jin, Zhichao
Yuan, Yuan
Hou, Wei
Hua, Baojin
Guo, Qiujun - Abstract:
- Abstract : Objective: P-cadherin can act both as a tumour suppressor and an oncogene. The clinical prognostic value of P-cadherin overexpression in breast cancer (BC) remains unclear. We conducted a study-level meta-analysis to determine whether P-cadherin expression can help predict prognosis in BC. Methods: A systematic literature search was performed to review eligible studies and clarify the relationship between P-cadherin overexpression and overall survival (OS), disease-free survival (DFS), pathological features, molecular subtypes and molecular phenotypes in BC. Results: Thirty-one studies including 12 332 patients were included. P-cadherin overexpression was correlated with significantly worse OS (HR=1.77, p<0.00001) and DFS (HR=1.96, p < 0.00001) than P-cadherin-negative. P-cadherin overexpression could lead to high histological grade (OR=3.33, p<0.00001) and lymph node metastasis (OR=1.62, p<0.00001). Moreover, P-cadherin overexpression was associated with low odds of the luminal A subtype and high odds of the human epidermal growth factor receptor-2 (HER2)-positive and triple-negative subtypes. P-cadherin expression led to low expression of oestrogen and progesterone receptor (OR=0.37 and OR=0.36, respectively, both p<0.00001) and high expression of HER2 (OR=2.31, p<0.00001), Ki-67 (OR=2.79, p<0.00001), epidermal growth factor receptor (OR=5.85, p<0.00001) and cytokeratin 5/6 (OR=6.79, p<0.00001). Conclusions: P-cadherin was found to be associated withAbstract : Objective: P-cadherin can act both as a tumour suppressor and an oncogene. The clinical prognostic value of P-cadherin overexpression in breast cancer (BC) remains unclear. We conducted a study-level meta-analysis to determine whether P-cadherin expression can help predict prognosis in BC. Methods: A systematic literature search was performed to review eligible studies and clarify the relationship between P-cadherin overexpression and overall survival (OS), disease-free survival (DFS), pathological features, molecular subtypes and molecular phenotypes in BC. Results: Thirty-one studies including 12 332 patients were included. P-cadherin overexpression was correlated with significantly worse OS (HR=1.77, p<0.00001) and DFS (HR=1.96, p < 0.00001) than P-cadherin-negative. P-cadherin overexpression could lead to high histological grade (OR=3.33, p<0.00001) and lymph node metastasis (OR=1.62, p<0.00001). Moreover, P-cadherin overexpression was associated with low odds of the luminal A subtype and high odds of the human epidermal growth factor receptor-2 (HER2)-positive and triple-negative subtypes. P-cadherin expression led to low expression of oestrogen and progesterone receptor (OR=0.37 and OR=0.36, respectively, both p<0.00001) and high expression of HER2 (OR=2.31, p<0.00001), Ki-67 (OR=2.79, p<0.00001), epidermal growth factor receptor (OR=5.85, p<0.00001) and cytokeratin 5/6 (OR=6.79, p<0.00001). Conclusions: P-cadherin was found to be associated with invasiveness and metastasis. P-cadherin expression can probably be a useful biomarker for predicting poor survival and may act as an independent prognostic predictor. … (more)
- Is Part Of:
- BMJ supportive & palliative care. Volume 12:Issue e6(2022)
- Journal:
- BMJ supportive & palliative care
- Issue:
- Volume 12:Issue e6(2022)
- Issue Display:
- Volume 12, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 12
- Issue:
- 6
- Issue Sort Value:
- 2022-0012-0006-0000
- Page Start:
- e893
- Page End:
- e905
- Publication Date:
- 2020-09-17
- Subjects:
- cancer -- breast -- prognosis
Palliative treatment -- Periodicals
Terminal care -- Periodicals
616.029 - Journal URLs:
- http://www.bmj.com/archive ↗
http://spcare.bmj.com/ ↗ - DOI:
- 10.1136/bmjspcare-2020-002204 ↗
- Languages:
- English
- ISSNs:
- 2045-435X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25657.xml